IMU Biosciences secures over $53m in Series A extension to map the immune system
The oversubscribed round was co-led by IQ Capital and Molten Ventures to expand the company's immune profiling platform.
≈ £39.4M at $1 = £0.7434 on 2 Jun 2026
A biotechnology company that maps the human immune system using single blood samples and artificial intelligence.
IMU Biosciences has extended its Series A funding round to over $53m in an oversubscribed transaction. The capital was co-led by IQ Capital and Molten Ventures, with participation from the British Business Bank, Meltwind, and existing backers. The London-based biotechnology firm has developed a platform that generates extensive immune data points from a single blood sample to support precision medicine and clinical research.
The fresh capital will support the continued scaling of the company's proprietary dataset and clinical validation efforts. IMU currently maintains one of the largest immune datasets globally, drawing on samples from thousands of individuals to improve diagnostics and treatment monitoring across oncology and transplantation.
Investor perspective
"When we first invested in IMU in 2024, we believed deep immune profiling combined with AI could transform precision medicine. Since then, the team has consistently delivered. The immune system sits at the heart of almost every disease, and IMU’s ability to analyse it at this resolution could redefine how treatments are matched to patients. We’re proud to be IMU’s largest shareholder and excited to support the company’s next phase of growth."
Inga Deakin
Partner, Molten
Investors
Categories
About the company
IMU Biosciences
Mapping the human immune system through advanced blood analysis.